Exact Mass: 1089.6235826

Exact Mass Matches: 1089.6235826

Found 23 metabolites which its exact mass value is equals to given mass value 1089.6235826, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

CDP-DG(18:2(9Z,11Z)/i-24:0)

{[(2R,3R,5R)-3,4-dihydroxy-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}({hydroxy[(2R)-2-[(22-methyltricosanoyl)oxy]-3-[(9Z,11Z)-octadeca-9,11-dienoyloxy]propoxy]phosphoryl}oxy)phosphinate

C54H97N3O15P2 (1089.6394592)


CDP-DG(18:2(9Z,11Z)/i-24:0) is a cytidine diphosphate diacylglycerol or CDP-diacylglycerol (CDP-DG). CDP-diacylglycerol is an important branchpoint intermediate in eukaryotic phospholipid biosynthesis and could be a key regulatory molecule in phospholipid metabolism. It is a glycerophospholipid in which a cytidine diphosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. CDP-DG(18:2(9Z,11Z)/i-24:0), in particular, consists of one chain of (9Z,11Z)-octadecadienoic acid at the C-1 position and one chain of isotetracosanoic acid at the C-2 position. Cytidine diphosphate diacylglycerols are rarely noticed in analyses of lipid compositions of tissues, as they are present is such small amounts (perhaps only 0.05\\% or so of the total phospholipids).

   

CDP-DG(i-24:0/18:2(9Z,11Z))

{[(2R,3R,5R)-3,4-dihydroxy-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}({hydroxy[(2R)-3-[(22-methyltricosanoyl)oxy]-2-[(9Z,11Z)-octadeca-9,11-dienoyloxy]propoxy]phosphoryl}oxy)phosphinate

C54H97N3O15P2 (1089.6394592)


CDP-DG(i-24:0/18:2(9Z,11Z)) is a cytidine diphosphate diacylglycerol or CDP-diacylglycerol (CDP-DG). CDP-diacylglycerol is an important branchpoint intermediate in eukaryotic phospholipid biosynthesis and could be a key regulatory molecule in phospholipid metabolism. It is a glycerophospholipid in which a cytidine diphosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. CDP-DG(i-24:0/18:2(9Z,11Z)), in particular, consists of one chain of isotetracosanoic acid at the C-1 position and one chain of (9Z,11Z)-octadecadienoic acid at the C-2 position. Cytidine diphosphate diacylglycerols are rarely noticed in analyses of lipid compositions of tissues, as they are present is such small amounts (perhaps only 0.05\\% or so of the total phospholipids).

   

CDP-DG(a-21:0/20:3(6,8,11)-OH(5))

{[(2R,3S,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({hydroxy[(2R)-2-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}-3-[(18-methylicosanoyl)oxy]propoxy]phosphoryl}oxy)phosphinic acid

C53H93N3O16P2 (1089.6030758)


CDP-DG(a-21:0/20:3(6,8,11)-OH(5)) is an oxidized CDP-diacylglycerol (CDP-DG). Oxidized CDP-diacylglycerols are glycerophospholipids in which a cytidine diphosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized CDP-diacylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. CDP-DG(a-21:0/20:3(6,8,11)-OH(5)), in particular, consists of one chain of one 18-methyleicosanoyl at the C-1 position and one chain of 5-hydroxyeicosatetrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized CDP-DGs can be synthesized via three different routes. In one route, the oxidized CDP-DG is synthetized de novo following the same mechanisms as for CDP-DGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the CDP-DG backbone, mainly through the action of LOX (PMID: 33329396).

   

CDP-DG(20:3(6,8,11)-OH(5)/a-21:0)

{[(2R,3S,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({hydroxy[(2R)-3-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}-2-[(18-methylicosanoyl)oxy]propoxy]phosphoryl}oxy)phosphinic acid

C53H93N3O16P2 (1089.6030758)


CDP-DG(20:3(6,8,11)-OH(5)/a-21:0) is an oxidized CDP-diacylglycerol (CDP-DG). Oxidized CDP-diacylglycerols are glycerophospholipids in which a cytidine diphosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized CDP-diacylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. CDP-DG(20:3(6,8,11)-OH(5)/a-21:0), in particular, consists of one chain of one 5-hydroxyeicosatetrienoyl at the C-1 position and one chain of 18-methyleicosanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized CDP-DGs can be synthesized via three different routes. In one route, the oxidized CDP-DG is synthetized de novo following the same mechanisms as for CDP-DGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the CDP-DG backbone, mainly through the action of LOX (PMID: 33329396).

   

CDP-DG(i-21:0/20:3(6,8,11)-OH(5))

{[(2R,3S,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({hydroxy[(2R)-2-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}-3-[(19-methylicosanoyl)oxy]propoxy]phosphoryl}oxy)phosphinic acid

C53H93N3O16P2 (1089.6030758)


CDP-DG(i-21:0/20:3(6,8,11)-OH(5)) is an oxidized CDP-diacylglycerol (CDP-DG). Oxidized CDP-diacylglycerols are glycerophospholipids in which a cytidine diphosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized CDP-diacylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. CDP-DG(i-21:0/20:3(6,8,11)-OH(5)), in particular, consists of one chain of one 19-methyleicosanoyl at the C-1 position and one chain of 5-hydroxyeicosatetrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized CDP-DGs can be synthesized via three different routes. In one route, the oxidized CDP-DG is synthetized de novo following the same mechanisms as for CDP-DGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the CDP-DG backbone, mainly through the action of LOX (PMID: 33329396).

   

CDP-DG(20:3(6,8,11)-OH(5)/i-21:0)

{[(2R,3S,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({hydroxy[(2R)-3-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}-2-[(19-methylicosanoyl)oxy]propoxy]phosphoryl}oxy)phosphinic acid

C53H93N3O16P2 (1089.6030758)


CDP-DG(20:3(6,8,11)-OH(5)/i-21:0) is an oxidized CDP-diacylglycerol (CDP-DG). Oxidized CDP-diacylglycerols are glycerophospholipids in which a cytidine diphosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized CDP-diacylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. CDP-DG(20:3(6,8,11)-OH(5)/i-21:0), in particular, consists of one chain of one 5-hydroxyeicosatetrienoyl at the C-1 position and one chain of 19-methyleicosanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized CDP-DGs can be synthesized via three different routes. In one route, the oxidized CDP-DG is synthetized de novo following the same mechanisms as for CDP-DGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the CDP-DG backbone, mainly through the action of LOX (PMID: 33329396).

   
   

(-)-sanglifehrin A|Sanglifehrin A|SFA

(-)-sanglifehrin A|Sanglifehrin A|SFA

C60H91N5O13 (1089.6613035999999)


   
   

CDP-DG(a-21:0/20:3(6,8,11)-OH(5))

CDP-DG(a-21:0/20:3(6,8,11)-OH(5))

C53H93N3O16P2 (1089.6030758)


   

CDP-DG(20:3(6,8,11)-OH(5)/a-21:0)

CDP-DG(20:3(6,8,11)-OH(5)/a-21:0)

C53H93N3O16P2 (1089.6030758)


   

CDP-DG(i-21:0/20:3(6,8,11)-OH(5))

CDP-DG(i-21:0/20:3(6,8,11)-OH(5))

C53H93N3O16P2 (1089.6030758)


   

CDP-DG(20:3(6,8,11)-OH(5)/i-21:0)

CDP-DG(20:3(6,8,11)-OH(5)/i-21:0)

C53H93N3O16P2 (1089.6030758)


   

beta-D-GlcNAc-(1->4)-MDP-Lys(L18)

beta-D-GlcNAc-(1->4)-MDP-Lys(L18)

C51H91N7O18 (1089.6420266)


   

(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-N-[(4E,8E,12E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxytetradeca-4,8,12-trien-2-yl]hexacosa-5,8,11,14,17,20,23-heptaenamide

(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-N-[(4E,8E,12E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxytetradeca-4,8,12-trien-2-yl]hexacosa-5,8,11,14,17,20,23-heptaenamide

C58H91NO18 (1089.6235826)


   

(5Z,8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoct-4-en-2-yl]dotriaconta-5,8,11,14,17,20,23,26,29-nonaenamide

(5Z,8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoct-4-en-2-yl]dotriaconta-5,8,11,14,17,20,23,26,29-nonaenamide

C58H91NO18 (1089.6235826)


   

2',2'-n,n-dichloromethyltetrandrine

NA

Cl2N2O62+ (1089.628584)


{"Ingredient_id": "HBIN003742","Ingredient_name": "2',2'-n,n-dichloromethyltetrandrine","Alias": "NA","Ingredient_formula": "Cl2N2O62+","Ingredient_Smile": "C[N+]1(CCC2=C3C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=C(C(=C(C=C7CC[N+]6(C)CCl)OC)OC)OC3=C(C=C2)OC)OC)CCl.[Cl-].[Cl-]","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT15029","TCMID_id": "5418","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

(3s,6s,9r,10r,11s,12s,13e,15e,18s)-18-[(2e,4e,8s,9s)-10-[(2s,3r,4s,5s,6r,9s,11s)-9-ethyl-4,8-dihydroxy-3,5,11-trimethyl-1-oxa-7-azaspiro[5.5]undec-7-en-2-yl]-9-hydroxy-8-methyldeca-2,4-dien-2-yl]-5,8,10,12-tetrahydroxy-3-[(3-hydroxyphenyl)methyl]-6-isopropyl-11-methyl-9-(3-oxobutyl)-19-oxa-1,4,7,25-tetraazabicyclo[19.3.1]pentacosa-4,7,13,15-tetraene-2,20-dione

(3s,6s,9r,10r,11s,12s,13e,15e,18s)-18-[(2e,4e,8s,9s)-10-[(2s,3r,4s,5s,6r,9s,11s)-9-ethyl-4,8-dihydroxy-3,5,11-trimethyl-1-oxa-7-azaspiro[5.5]undec-7-en-2-yl]-9-hydroxy-8-methyldeca-2,4-dien-2-yl]-5,8,10,12-tetrahydroxy-3-[(3-hydroxyphenyl)methyl]-6-isopropyl-11-methyl-9-(3-oxobutyl)-19-oxa-1,4,7,25-tetraazabicyclo[19.3.1]pentacosa-4,7,13,15-tetraene-2,20-dione

C60H91N5O13 (1089.6613035999999)


   

(8e,10e,12e,25e)-5,16,21,32,33,36-hexabromo-12,25-bis(hydroxyimino)-2,18-dioxa-10,27-diazapentacyclo[28.2.2.2¹⁴,¹⁷.1³,⁷.1¹⁹,²³]octatriaconta-1(32),3(38),4,6,8,10,14,16,19(35),20,22,26,30,33,36-pentadecaene-4,11,20,26-tetrol

(8e,10e,12e,25e)-5,16,21,32,33,36-hexabromo-12,25-bis(hydroxyimino)-2,18-dioxa-10,27-diazapentacyclo[28.2.2.2¹⁴,¹⁷.1³,⁷.1¹⁹,²³]octatriaconta-1(32),3(38),4,6,8,10,14,16,19(35),20,22,26,30,33,36-pentadecaene-4,11,20,26-tetrol

C34H24Br6N4O8 (1089.6694224)


   

5,16,21,32,33,36-hexabromo-4,20-dihydroxy-12,25-bis(hydroxyimino)-2,18-dioxa-10,27-diazapentacyclo[28.2.2.2¹⁴,¹⁷.1³,⁷.1¹⁹,²³]octatriaconta-1(32),3(38),4,6,8,14,16,19(35),20,22,30,33,36-tridecaene-11,26-dione

5,16,21,32,33,36-hexabromo-4,20-dihydroxy-12,25-bis(hydroxyimino)-2,18-dioxa-10,27-diazapentacyclo[28.2.2.2¹⁴,¹⁷.1³,⁷.1¹⁹,²³]octatriaconta-1(32),3(38),4,6,8,14,16,19(35),20,22,30,33,36-tridecaene-11,26-dione

C34H24Br6N4O8 (1089.6694224)


   

(3s,6s,9r,10r,11s,12s,13e,15e,18s,21s)-18-[(2e,4e,8s,9s)-10-[(2s,3r,4s,5s,6r,9s,11s)-9-ethyl-4,8-dihydroxy-3,5,11-trimethyl-1-oxa-7-azaspiro[5.5]undec-7-en-2-yl]-9-hydroxy-8-methyldeca-2,4-dien-2-yl]-5,8,10,12-tetrahydroxy-3-[(3-hydroxyphenyl)methyl]-6-isopropyl-11-methyl-9-(3-oxobutyl)-19-oxa-1,4,7,25-tetraazabicyclo[19.3.1]pentacosa-4,7,13,15-tetraene-2,20-dione

(3s,6s,9r,10r,11s,12s,13e,15e,18s,21s)-18-[(2e,4e,8s,9s)-10-[(2s,3r,4s,5s,6r,9s,11s)-9-ethyl-4,8-dihydroxy-3,5,11-trimethyl-1-oxa-7-azaspiro[5.5]undec-7-en-2-yl]-9-hydroxy-8-methyldeca-2,4-dien-2-yl]-5,8,10,12-tetrahydroxy-3-[(3-hydroxyphenyl)methyl]-6-isopropyl-11-methyl-9-(3-oxobutyl)-19-oxa-1,4,7,25-tetraazabicyclo[19.3.1]pentacosa-4,7,13,15-tetraene-2,20-dione

C60H91N5O13 (1089.6613035999999)


   

18-(10-{9-ethyl-4,8-dihydroxy-3,5,11-trimethyl-1-oxa-7-azaspiro[5.5]undec-7-en-2-yl}-9-hydroxy-8-methyldeca-2,4-dien-2-yl)-5,8,10,12-tetrahydroxy-3-[(3-hydroxyphenyl)methyl]-6-isopropyl-11-methyl-9-(3-oxobutyl)-19-oxa-1,4,7,25-tetraazabicyclo[19.3.1]pentacosa-4,7,13,15-tetraene-2,20-dione

18-(10-{9-ethyl-4,8-dihydroxy-3,5,11-trimethyl-1-oxa-7-azaspiro[5.5]undec-7-en-2-yl}-9-hydroxy-8-methyldeca-2,4-dien-2-yl)-5,8,10,12-tetrahydroxy-3-[(3-hydroxyphenyl)methyl]-6-isopropyl-11-methyl-9-(3-oxobutyl)-19-oxa-1,4,7,25-tetraazabicyclo[19.3.1]pentacosa-4,7,13,15-tetraene-2,20-dione

C60H91N5O13 (1089.6613035999999)